Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis
Drug guidance

Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis

Condition

Kidney

16 September 2025

-

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Sucroferric oxyhydroxide 500 mg chewable tablet for treating hyperphosphataemia in patients with end-stage renal disease on haemodialysis or peritoneal dialysis who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia.

Funding status

Sucroferric oxyhydroxide 500 mg chewable tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.

Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis (Published 16 Sep 2025) [PDF, 122 KB]

PES Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage kidney disease on dialysis (Published 16 Sep 2025) [PDF, 128 KB]

Back to top